Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 25;12:885236. doi: 10.3389/fonc.2022.885236

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Wongpattaraworakul, Gibson-Corley, Choi, Buchakjian, Lanzel, Rajan KD and Simons

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Prognostic impact of combined EGFR and CD4 expression in OSCCs. (A) Shown are images of no [0], low [1+], moderate [2+], and strong [3+] CD4 expression scores. (B) Kaplan-Meier estimates of the overall survival of CD4+ (2+, 3+) and CD4- (0, 1+) patients. (C) Percentages of tumors with CD4+ and CD4- expression based on EGFR status. (D, E) Kaplan-Meier estimates of overall survival of CD4+ and CD4- patients based on EGFR+ (D) or EGFR- (E) tumor expression. (F) Percentages of tumors with CD4+ and CD4- expression based on EGFR and CD3 status. HR, hazard ratio; CI, 95% confidence interval.